Huaan Securities released a research report on April 21 stating that it gave Zejing Pharmaceutical (688266.SH) a purchase rating. The main reasons for the rating include: 1) steady increase in operational efficiency and positive operating cash flow for the first time; 2) existing commercial products have resumed growth, and 24H1 commercialization highlights are concentrated; 3) the subsequent arrangement of BIC and FIC pipelines, and the dual anti-triple antibody platform has entered the verification period. (Mainichi Keizai Shimbun)
华安证券4月21日发布研报称，给予泽璟制药（688266.SH）买入评级。评级理由主要包括：1）运营增效稳扎稳打，经营性现金流首次为正；2）现有商业化产品恢复增长，24H1商业化看点密集；3）后续BIC、FIC管线排布，双抗三抗平台进入验证期。（每日经济新闻）
Huaan Securities released a research report on April 21 stating that it gave Zejing Pharmaceutical (688266.SH) a purchase rating. The main reasons for the rating include: 1) steady increase in operational efficiency and positive operating cash flow for th
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.